Radiation and immunotherapy team up against hard-to-treat lymphoma
NCT ID NCT07634289
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether giving radiation therapy before the immunotherapy drugs obinutuzumab and glofitamab can improve outcomes for people with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). About 40 adults who have already tried at least two prior treatments will receive radiation followed by 12 cycles of drug therapy. The main goal is to see how many patients achieve a complete response without severe side effects, with follow-up lasting up to 5 years.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FOLLICULAR LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Austin Hospital
Heidelberg, Victoria, 3084, Australia
-
Fiona Stanley Hospital
Murdoch, Western Australia, Australia
-
Flinders Medical Centre
Bedford Park, South Australia, 5042, Australia
-
Princess Alexandra Hospital
Woolloongabba, Queensland, 4102, Australia
-
Townsville University Hospital
Douglas, Queensland, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can immune cells plus a checkpoint drug outsmart lymphoma?
- Can a simple blood test spot lymphoma earlier?
- Can a cancer biopsy predict who responds to a new immunotherapy?
- What happens years after CAR-T therapy? a study aims to find out
- Can a reshaped chemo combo tame lymphoma with fewer side effects?
- Can a single shot build a cancer army inside the body?